Lockheed Martin Investment Management Co. Sells 520 Shares of Thermo Fisher Scientific Inc. $TMO

Lockheed Martin Investment Management Co. lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.3% during the 2nd quarter, HoldingsChannel reports. The firm owned 7,680 shares of the medical research company’s stock after selling 520 shares during the period. Lockheed Martin Investment Management Co.’s holdings in Thermo Fisher Scientific were worth $3,114,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of TMO. Brighton Jones LLC lifted its holdings in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. DAVENPORT & Co LLC lifted its holdings in shares of Thermo Fisher Scientific by 13.7% during the 1st quarter. DAVENPORT & Co LLC now owns 4,668 shares of the medical research company’s stock valued at $2,323,000 after purchasing an additional 562 shares in the last quarter. FSM Wealth Advisors LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $205,000. Finally, Private Trust Co. NA boosted its position in shares of Thermo Fisher Scientific by 7.1% during the first quarter. Private Trust Co. NA now owns 4,883 shares of the medical research company’s stock worth $2,430,000 after buying an additional 324 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Activity

In other news, CEO Marc N. Casper sold 7,250 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $566.10, for a total value of $4,104,225.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at $64,400,668.20. This trade represents a 5.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 54,420 shares of company stock valued at $28,134,684 over the last three months. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.4%

Shares of Thermo Fisher Scientific stock opened at $556.32 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The stock has a market cap of $210.07 billion, a P/E ratio of 32.14, a P/E/G ratio of 3.27 and a beta of 0.77. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The business’s 50 day moving average is $509.50 and its 200-day moving average is $456.80.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the prior year, the business posted $5.28 EPS. The business’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Evercore ISI boosted their target price on Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Argus boosted their target price on Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a research note on Wednesday. Scotiabank upgraded Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Finally, Citigroup boosted their target price on Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a “neutral” rating in a research note on Thursday, October 23rd. Nineteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.